## **Elotuzumab Idiotypic Antibody**

Goat Polyclonal Affinity Purified

Catalog No. A85-004A



**APPLICATIONS** ELISA, IFE

AMOUNT 100 µl at 1 mg/ml

CONCENTRATION 1000 μg/ml

**STORAGE/SHELF LIFE** 2 – 8° C / 2 years from date of receipt

PHYSICAL STATE Liquid

BUFFER Phosphate Buffered Saline (PBS) containing 0.09% Sodium Azide

ISOTYPE IgG
ORIGIN USA

**PRODUCTION** The antibody was isolated by affinity chromatography using antigen coupled to agarose

**PROCEDURES** bead

Antibody concentration was determined by extinction coefficient: absorbance at 280 nm of

1.4 equals 1.0 mg of IgG.

**APPLICATIONS** Centrifuge tube to remove product from lid. Optimal working dilutions should be determined

experimentally by the investigator. Prepare working dilution immediately before use.

ELISA 1:1,000 - 1:30,000

Immunofixation Neat


ADDITIONAL INFO https://www.bethyl.com/product/A85-004A

Use the link above to view SDS, a current list of citations, and other product specific information.


This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc.

Brian McWilliams, PhD

Date: May 1, 2021



Shifting (Mitigation of) Elotuzumab in Myeloma plasma using modified anti-Elotuzumab idiotype antibody in a serum immunofixation assay. Samples: All lanes contain Human IgG-Kappa plasma samples. Lanes 1-4 contain the one patient sample, Lanes 5-8 contain a different patient sample. Lanes 1 & 5 contain only the patient sample, Lanes 3, 4, 7 & 8 contain patient samples + elotuzumab, and Lanes 4 & 8 also contain modified Anti-Elotuzumab (A85-004A-modified). Row A samples were reacted with anti-human IgG antisera, Row B samples were reacted with anti-human Kappa light chain. Lane 2 & 6 are serum protein electrophoresis of the patient samples without elotuzumab.



Inhibition of Elotuzumab–HRP binding to Recombinant SLAMF7 by ELISA. Samples: Solid phase immobilized recombinant SLAMF7 incubated with HRP conjugated Elotuzumab (0.5 ug/ml) in the presence increasing concentrations of Goat anti–Elotuzumab idiotypic antibody (A85–004A).